Activated FGFR2 as a Viable Therapeutic Target in a Subset of Ovarian Cancers

摘要: Abstract : Ovarian cancer is the leading cause of death from gynecologic malignancies in Western world. Fibroblast growth factor receptor (FGFR) signaling has been implicated to play a role ovarian tumorigenesis. Given our recent report activating mutations FGFR2 endometrioid endometrial tumors and similarities molecular genetics cancer, we hypothesized that may also occur subset tumors, particularly subtype. Methods: Six exons were sequenced 120 representing various histotypes cancer. Results: Mutation was detected at low frequency (1/46, 2.2%) serous (1/41, 2.4%) No clear cell, mucinous, or mixed histology cell lines tested. Functional characterization confirmed result activation. Conclusions: Despite incidence development validation anti-FGFR agents other types allow for future use these small patients whose possess mutations.